Why did Vir Biotechnology (VIR) stock move recently?

On 8/25/2026, Vir Biotechnology moved +8.1% — Vir Biotechnology shares rose ~8% on continued post-Q2 earnings momentum, fueled by the Astellas collaboration's upfront revenue and equity investment that drove a swing to profitability and boosted cash/investments above $1B, alongside optimism around pipeline catalysts including VIR-5500 data. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Vir Biotechnology (VIR) overvalued or fairly valued?

MarketChacha shows Vir Biotechnology's valuation in context — a forward P/E of about -4.6, a price-to-book of about 2.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Vir Biotechnology's revenue?

Vir Biotechnology reported revenue of $68.6M for FY2025, with net profit of $-438.0M, per official filings.

What is the share price of Vir Biotechnology (VIR)?

Vir Biotechnology last traded at $11.39 (-0.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Vir Biotechnology

VIR · NYSE · Healthcare · United States

Snapshot

TickerVIR

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees367

HeadquartersSan Francisco, United States

Websitewww.vir.bio

Filings tracked19

About Vir Biotechnology

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Who owns it

Insiders6.6%
Institutions84.2%
Public & other9.2%

334 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.22%
Arch Venture Management, Llc7.50%
Vanguard Portfolio Management LLC6.79%
SB Investment Advisers (UK) LTD6.47%
State Street Corporation5.89%
GSK plc5.05%
Vanguard Capital Management LLC3.78%
Point72 Asset Management, L.P.3.35%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -57.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-713.7% → -638.9%

Margin has expanded by about 74.8 points — the business is getting more profitable.

Return on equity-57.2%

Latest ROE of -57.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $6.3M · EPS -0.65

Est. earnings growth -110.8%

Next fiscal year

Rev $73.6M · EPS -2.56

Est. earnings growth -43.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$68.6M

Net margin

-638.9%

ROE

-57.2%

Revenue CAGR (2y)

-10.8%

EPS (FY2025)

-3.16

Net profit (FY2025)

$-438.0M

Ask MarketChacha about VIR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
Vir Biotechnology shares rose ~8% on continued post-Q2 earnings momentum, fueled by the Astellas collaboration's upfront revenue and equity investment that drove a swing to profitability and boosted cash/investments above $1B, alongside optimism around pipeline catalysts including VIR-5500 data.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$68.6M	$-438.0M	-3.16	-638.9%	-57.2%
FY2024	$74.2M	$-522.0M	-3.83	-703.4%	-45.4%
FY2023	$86.2M	$-615.1M	-4.59	-713.7%	-38.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$238.9M	$80.1M	0.47	33.5%
2026Q1	$-29,000	$-125.7M	-0.85	—
2025Q3	$240,000	$-163.1M	-1.17	-67975.4%
2025Q2	$1.2M	$-111.0M	-0.80	-9139.9%
2025Q1	$3.0M	$-121.0M	-0.88	-3989.6%
2024Q3	$2.4M	$-213.7M	-1.56	-8979.7%
2024Q2	$3.1M	$-138.4M	-1.02	-4500.1%
2024Q1	$56.4M	$-65.3M	-0.48	-115.8%
2023Q3	$2.6M	$-163.4M	-1.22	-6192.2%
2023Q2	$3.8M	$-194.8M	-1.45	-5129.7%
2023Q1	$63.0M	$-141.0M	-1.06	-223.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Executive/director change
SEC7/24/2026material
8-K — Executive/director change
SEC6/10/2026material
8-K — Executive/director change, Shareholder vote results
SEC5/28/2026material
10-Q filing
SEC5/7/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material
8-K — Executive/director change
SEC4/10/2026material
8-K — Executive/director change
SEC3/4/2026material
8-K — Other events
SEC3/2/2026material
8-K — Material agreement, Exhibits
SEC2/26/2026material
8-K — Material agreement, Results of operations, Unregistered equity sale, Other events, Exhibits
SEC2/23/2026material
10-K filing
SEC2/23/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Material agreement, Other events, Exhibits
SEC12/16/2025material
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.